|
| 33427765 | Efficacy, Pharmacokinetics, and Safety Over 48 Weeks With Ibalizumab-Based Therapy in Treatment-Experienced Adults Infected With HIV-1: A Phase 2a Study. | Journal of acquired immune deficiency syndromes (1999) | 2021 |
| 32860360 | Vitamin D Assessment Over 48 Weeks in Treatment-Naive HIV Individuals Starting Lopinavir/Ritonavir Monotherapy. | Current HIV Research | 2021 |
| 33214937 | COVID-19 Coexisting With the Human Immunodeficiency Virus: A Case Report. | | 2020 |
| 31879782 | Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Rapid-Initiation Model of Care for Human Immunodeficiency Virus Type 1 Infection: Primary Analysis of the DIAMOND Study. | Clinical Infectious Diseases | 2020 |
| 33072804 | Human Immunodeficiency Virus in the State of Texas of the United States: Past Reflections, Present Shortcomings, and Future Needs of the Public Health Response. | Open Forum Infectious Diseases | 2020 |
| 28993180 | Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial. | Lancet HIV | 2018 |
| 28088870 | Fatal Relapse of Myelodysplastic Syndrome in a Patient with HIV/Hepatitis C Coinfection Treated with Simeprevir/Sofosbuvir. | Journal of the International Association of Providers of AIDS Care | 2017 |
| 29210627 | Pharmacokinetic analysis of nevirapine extended release 400 mg once daily vs nevirapine immediate release 200 mg twice daily formulation in treatment-naïve patients with HIV-1 infection. | | 2017 |
| 26627107 | Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study. | J Acquir Immune Defic Syndr | 2016 |
| 26849060 | Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed Patients. | PLoS ONE | 2016 |
| 26821578 | Fecal Transplantation for Clostridium Difficile-"All Stool May Not Be Created Equal". | Journal of the International Association of Providers of AIDS Care | 2016 |
| 26636929 | A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus. | AIDS | 2016 |
| 26196502 | Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. | N Engl J Med | 2015 |
| 25706092 | Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. | JAMA | 2015 |
| 25867913 | Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study. | J Acquir Immune Defic Syndr | 2015 |
| 26286337 | Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF. | Patient | 2015 |
| 24908551 | Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial. | Lancet Infect Dis | 2014 |
| 25394009 | Safety and efficacy of ombitasvir - 450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens. | J Int AIDS Soc | 2014 |
| 24346640 | A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. | Journal of acquired immune deficiency syndromes (1999) | 2014 |
| 23337366 | A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results | Journal of acquired immune deficiency syndromes (1999) | 2013 |
| 22730929 | Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study. | AIDS Research and Human Retroviruses | 2013 |
| 24144895 | Long-term safety study of fosamprenavir-containing regimens in HIV-1-infected patients. | HIV Clinical Trials | 2013 |
| 21878055 | Risk factors for vitamin D deficiency in HIV-infected patients in the south central United States. | AIDS Research and Human Retroviruses | 2012 |
| 22748590 | Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double- | Lancet, The | 2012 |
| 22634184 | Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: final results of two randomized phase III trials. | Journal of Infection | 2012 |
| 22416849 | Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE. | HIV Medicine | 2012 |
| 21817198 | Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients. | Antiviral Therapy | 2011 |
| 21317794 | Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5/CCR2 antagonist, in HIV-1-infected, treatment-experienced, CCR5 antagonist-naive subjects. | Journal of acquired immune deficiency syndromes (1999) | 2011 |
| 21811136 | Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection. | AIDS | 2011 |
| 22180523 | Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results. | HIV Clinical Trials | 2011 |
| 20134329 | Efficacy, safety, and tolerability of etravirine with and without darunavir/ritonavir or raltegravir in treatment-experienced patients: analysis of the etravirine early access program in the United States. | Journal of acquired immune deficiency syndromes (1999) | 2010 |
| 20841439 | Lopinavir/ritonavir dosage form affects quality of life during monotherapy in HIV-positive adults. | Journal of the International Association of Physicians in AIDS Care | 2010 |
| 21051598 | The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. | Science | 2010 |
| 20134330 | Similar safety and efficacy of once- and twice-daily lopinavir/ritonavir tablets in treatment-experienced HIV-1-infected subjects at 48 weeks. | Journal of acquired immune deficiency syndromes (1999) | 2010 |
| 19225400 | A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks. | Journal of acquired immune deficiency syndromes (1999) | 2009 |
| 19292590 | Predictors of loss of virologic response in subjects who simplified to lopinavir/ritonavir monotherapy from lopinavir/ritonavir plus zidovudine/lamivudine. | AIDS Research and Human Retroviruses | 2009 |
| 19563238 | Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40263). | AIDS Research and Human Retroviruses | 2009 |
| 18234149 | Experience with darunavir in HIV-infected adults enrolled in a US expanded access program: results from a single center. | Current Medical Research and Opinion | 2008 |
| 18580340 | Resolution of severe cryptosporidial diarrhea with rifaximin in patients with AIDS. | Journal of acquired immune deficiency syndromes (1999) | 2008 |
| 18389895 | Health-related quality of life and tolerability in treatment-experienced HIV-1-infected patients on tipranavir versus comparator regimens. | Antiviral Therapy | 2008 |
| 18661634 | Antiretroviral rounds. Resistance: what you don't know--can it hurt you? | AIDS clinical care | 2008 |
| 18809940 | Safety and efficacy of enfuvirtide in combination with darunavir-ritonavir and an optimized background regimen in treatment-experienced human immunodeficiency virus-infected patients: the below the level of quantification study. | Antimicrobial Agents and Chemotherapy | 2008 |
| 17263650 | Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type-1 infected patients. | AIDS Research and Human Retroviruses | 2007 |
| 16890834 | The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. | Lancet | 2006 |
| 17208898 | Once-daily abacavir/lamivudine/zidovudine plus tenofovir for the treatment of HIV-1 infection in antiretroviral-naïve subjects: a 48-week pilot study. | HIV Clinical Trials | 2006 |
| 16861096 | Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study. | Clinical Therapeutics | 2006 |
| 16951643 | A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. | Journal of acquired immune deficiency syndromes (1999) | 2006 |
| 17051503 | Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial. | Clin Infect Dis | 2006 |
| 16208820 | HAART at 10: an interview with Joseph Gathe. | Research initiative, treatment action : RITA | 2005 |
| 15747240 | Administration of protein-conjugate pneumococcal vaccine to patients who have invasive disease after splenectomy despite their having received 23-valent pneumococcal polysaccharide vaccine. | Journal of Infectious Diseases | 2005 |